Eosinophilic Esophagitis

Eosinophilic Esophagitis (EoE): A Comprehensive Clinical Monograph

1. Introduction and Clinical Overview

Eosinophilic Esophagitis (EoE) is a chronic, immune-mediated clinicopathologic esophageal disorder characterized by esophageal dysfunction and eosinophil-predominant inflammation. Unlike gastroesophageal reflux disease (GERD), which is driven by acid exposure, EoE is primarily an allergen-driven condition. It is now recognized as a leading cause of dysphagia and esophageal food impaction in both pediatric and adult populations.

The clinical hallmark of EoE is the presence of ≥15 eosinophils per high-power field (eos/hpf) on esophageal biopsy, in the absence of other causes of esophageal eosinophilia. As a progressive fibrostenotic disease, if left untreated, it often evolves from an inflammatory phenotype to a fibrostenotic phenotype, resulting in strictures, narrowing, and an increased risk of medical emergencies like food bolus obstruction.

2. Etiology and Pathophysiology

The pathogenesis of EoE involves a complex interplay between genetic predisposition, environmental triggers, and immune dysregulation.

The "Four-Hit" Hypothesis

1. Genetic Susceptibility: Genome-wide association studies (GWAS) have identified specific loci, such as CAPN14 (calpain-14), which is highly expressed in esophageal epithelial cells and is upregulated in EoE.
2. Barrier Dysfunction: Compromised integrity of the esophageal epithelial barrier (via loss of filaggrin or other tight junction proteins) allows for increased permeability to dietary antigens.
3. Antigen Exposure: Environmental allergens (typically food proteins like milk, wheat, soy, eggs, nuts, and seafood) penetrate the epithelium.
4. Immune Activation: The immune system mounts a Type 2 inflammatory response, primarily driven by T-helper 2 (Th2) cytokines, most notably Interleukin-5 (IL-5), IL-13, and eotaxin-3.

Mechanism of Remodeling

Chronic inflammation leads to the activation of esophageal fibroblasts. These cells secrete transforming growth factor-beta (TGF-β), leading to subepithelial fibrosis. This structural remodeling causes the esophageal wall to lose compliance, manifesting clinically as rings, furrows, and strictures.

3. Clinical Presentation and Staging

Standard Presentation by Age Group

• Pediatric (1–12 years): Often non-specific. Symptoms include failure to thrive, abdominal pain, vomiting, and food refusal.
• Adolescent/Adult: Predominantly dysphagia (difficulty swallowing), retrosternal chest pain, and the sensation of food "getting stuck." Patients often develop compensatory behaviors, such as prolonged chewing, excessive fluid intake, or avoiding specific food textures.

The EoE Endoscopic Reference Score (EREFS)

To standardize the assessment of endoscopic findings, clinicians utilize the EREFS classification system:

4. Differential Diagnosis

Because esophageal eosinophilia is not exclusive to EoE, it is critical to rule out other conditions before confirming a diagnosis.

• GERD: The most common mimic. Proton pump inhibitor-responsive esophageal eosinophilia (PPI-REE) is now considered a subset of EoE in some classifications.
• Eosinophilic Gastroenteritis (EGE): Involves other parts of the GI tract.
• Connective Tissue Diseases: Such as scleroderma or eosinophilic vasculitis.
• Infections: Parasitic infections, fungal esophagitis (Candida), or viral esophagitis (HSV/CMV).
• Drug Hypersensitivity: Medication-induced esophagitis.
• Celiac Disease: Though primarily small intestinal, it can occasionally manifest with esophageal symptoms.

5. Diagnostic Protocol

The diagnosis of EoE is a collaborative effort between the gastroenterologist and the pathologist.

Key Diagnostic Steps

1. Clinical History: Assessment of dysphagia score and dietary triggers.
2. Endoscopy (EGD): Must include a minimum of 6 biopsies taken from the proximal, mid, and distal esophagus.
3. Histopathology: Confirmation of ≥15 eos/hpf.
4. PPI Trial: An 8-week course of high-dose proton pump inhibitors is often required to exclude GERD-related eosinophilia.
5. Allergy Testing: Skin prick or patch testing may identify potential food triggers, though these tests have limited predictive value for dietary elimination success.

6. Management and Therapeutic Strategies

Management is generally divided into dietary, pharmacological, and mechanical approaches.

Therapeutic Options

• Dietary Elimination:
  • Six-Food Elimination Diet (SFED): Removal of dairy, wheat, soy, eggs, nuts, and seafood.
  • Elemental Diet: Amino-acid-based formula (highly effective but socially restrictive).
• Pharmacological:
  • Topical Corticosteroids: Swallowed (not inhaled) fluticasone or budesonide slurries.
  • Biologics: Dupilumab (IL-4/IL-13 inhibitor) is currently the first FDA-approved therapy for EoE in adults and adolescents.
• Mechanical:
  • Esophageal Dilation: Used for patients with established strictures. Note: Must be performed cautiously due to the increased risk of esophageal perforation in EoE patients.

7. Risks and Complications

• Esophageal Food Impaction: A medical emergency requiring urgent endoscopy.
• Strictures: Permanent narrowing requiring dilation.
• Esophageal Perforation: A rare but serious risk during dilation procedures.
• Nutritional Deficiencies: Potential for weight loss and malnutrition due to food avoidance.
• Psychosocial Burden: Anxiety related to eating and the chronic nature of the illness.

8. Long-Term Prognosis

EoE is a chronic condition that typically requires lifelong management. While it does not decrease life expectancy, it significantly impacts quality of life. Patients who maintain histological remission (low eosinophil counts) show significantly less fibrotic remodeling over time. Adherence to therapy is the single most important factor in preventing long-term esophageal damage.

9. Frequently Asked Questions (FAQ)

1. Is EoE the same as an allergy?
EoE is an immune-mediated condition triggered by food antigens, but it is not a classic IgE-mediated anaphylactic allergy. It is a delayed, T-cell-mediated hypersensitivity reaction.

2. Can EoE be cured?
There is no "cure" in the sense of permanent reversal, but the condition can be managed into complete remission through diet or medication.

3. Will I need surgery?
Surgery is rarely indicated. Most patients are managed with diet, medication, or occasional endoscopic dilation.

4. What is the most common symptom in adults?
Dysphagia (difficulty swallowing) and the sensation of food getting stuck in the chest.

5. How many biopsies are needed?
Current guidelines suggest at least 6 biopsy samples taken from multiple levels of the esophagus to avoid sampling error.

6. Is EoE related to asthma?
Yes, there is a strong association. Many patients with EoE also have a history of asthma, eczema, or allergic rhinitis (atopic triad).

7. Does taking a PPI mean I don't have EoE?
Not necessarily. Some patients with EoE respond to PPIs (PPI-REE). If your eosinophil count drops after a PPI trial, you may still have EoE that is sensitive to acid-suppression therapy.

8. Can I outgrow EoE?
Unlike some childhood food allergies, EoE is rarely "outgrown" and is generally considered a lifelong chronic condition in adults.

9. What are the "Red Flags" for an EoE patient?
Inability to swallow liquids, complete food bolus impaction, unintentional weight loss, or severe chest pain. These require immediate medical attention.

10. What is the role of Dupilumab?
Dupilumab is a monoclonal antibody that targets the IL-4 receptor, effectively blocking the inflammatory pathway that recruits eosinophils to the esophagus. It is highly effective for patients who fail dietary or steroid therapies.

10. Conclusion

Eosinophilic Esophagitis represents a paradigm shift in our understanding of esophageal disease. By moving away from the traditional "acid-reflux" model and embracing an immunological, allergy-based framework, clinicians can better diagnose and treat this condition. Through a combination of targeted biopsy, dietary modification, and advanced biologic therapy, patients with EoE can achieve sustained remission and prevent the long-term complications of fibrotic esophageal remodeling.

Disclaimer: This guide is for educational purposes only. Always consult with a board-certified gastroenterologist for diagnosis and treatment plans.